In a phase 2 study, in patients with ER/PR-negative and androgen receptor positive advanced breast cancer, the anti-androgen agent bicalutaminde has shown a 6 month clinical benefit rate of 19% and the median progression-free survival was 12 weeks [28]. Here, ESR1 is linked to breast carcinoma.